Enlicitide Wins FDA Nod as First Oral PCSK9 Inhibitor
Contents10 sections
The U.S. Food and Drug Administration has approved LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor cleared to lower LDL cholesterol in adults with hypercholesterolemia. Merck's once-daily 20 mg tablet cut LDL-C by 56% versus placebo at 24 weeks in the Phase 3 CORALreef Lipids trial, giving patients a pill alternative to injectable PCSK9 therapies.
Key Takeaways
The FDA approved Merck's LIPFENDRA (enlicitide) 20 mg on July 16, 2026 as the first oral PCSK9 inhibitor for LDL-C lowering.
In CORALreef Lipids, enlicitide lowered LDL-C by 56% versus placebo at week 24; in CORALreef HeFH the reduction was 59%.
A cardiovascular outcomes trial is ongoing, so it is not yet known whether the drug reduces heart attacks or deaths.
What did the FDA approve?
Merck (NYSE: MRK), known as MSD outside the United States and Canada, said the FDA approved LIPFENDRA tablets as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The company described the drug as the first oral PCSK9 inhibitor shown to lower LDL-C, according to its approval announcement.
The FDA had granted enlicitide a Commissioner's National Priority Voucher in December 2025, a designation Merck credited for the review timeline. The approval was also carried on the Business Wire newswire.
How does enlicitide work?
PCSK9 is a protein that breaks down LDL receptors, the cell-surface proteins that clear LDL cholesterol from the blood. Blocking PCSK9 leaves more receptors intact, which lowers circulating LDL-C. Enlicitide is a novel macrocyclic peptide that binds PCSK9 and blocks its interaction with LDL receptors, delivering that effect in a once-daily pill rather than an injection.
What the CORALreef Lipids trial showed
CORALreef Lipids (NCT05952856) enrolled 2,912 adults with or at risk for atherosclerotic cardiovascular disease who were on background lipid-lowering therapy or had documented statin intolerance. Participants were randomized 2:1 to 20 mg of once-daily enlicitide or placebo.
LDL-C fell 56% versus placebo at week 24 (95% CI: -61, -51; p<0.001).
The reduction was sustained at about 48% versus placebo at week 52.
Non-HDL-C dropped 53% and ApoB dropped 50% versus placebo at week 24.
67.5% of treated patients hit a target of at least a 50% LDL-C cut plus LDL-C under 55 mg/dL, versus 1.2% on placebo.
The one-year efficacy and secondary-endpoint figures were reported in Merck's CORALreef Lipids readout presented at the American Heart Association Scientific Sessions in November 2025.
Results in familial hypercholesterolemia
The approval also drew on CORALreef HeFH, which tested enlicitide in adults with an inherited form of high cholesterol. In that trial the drug lowered LDL-C by 59% versus placebo at week 24. The most common side effects seen more often than with placebo were dizziness (9% versus 4%) and diarrhea (7% versus 2%).
Safety profile and open questions
In CORALreef Lipids, adverse events were similar between the enlicitide and placebo groups, and discontinuations because of side effects were low at 3.1% for enlicitide versus 4.1% for placebo. An important caveat remains: a cardiovascular outcomes trial is still running, and Merck notes it is not yet known whether the drug reduces cardiovascular illness or death. Reuters reported the late-stage program as a potential blockbuster when the first CORALreef data emerged, in its June 2025 coverage.
What it means for patients and the PCSK9 market
Injectable PCSK9 inhibitors such as evolocumab and alirocumab lower LDL-C sharply but require dosing every two to four weeks, and uptake has lagged. An oral option could widen access for patients who resist injections or miss LDL-C goals on statins alone. Merck has not disclosed pricing or a launch date, and payer coverage will shape how quickly the pill reaches patients.
Related NovaPharma coverage
Eli Lilly's donanemab wins FDA approval in early Alzheimer's disease
J&J reports positive Phase 3 Tremfya data in ulcerative colitis
Merck's Harpoon Therapeutics acquisition and its oncology pipeline
Frequently Asked Questions
Is there an oral PCSK9 inhibitor available now?
Yes. On July 16, 2026 the FDA approved Merck's LIPFENDRA (enlicitide) 20 mg tablets, the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia. Merck did not disclose pricing or a launch date in its approval announcement.
How much does enlicitide lower LDL cholesterol?
In the Phase 3 CORALreef Lipids trial, enlicitide reduced LDL-C by 56% versus placebo at week 24, and by 59% versus placebo in the CORALreef HeFH trial. Reductions were sustained to week 52 at about 48% versus placebo.
How is an oral PCSK9 inhibitor different from injectable ones?
Existing PCSK9 inhibitors such as evolocumab and alirocumab are injected. Enlicitide is a novel macrocyclic peptide taken as a once-daily pill that binds PCSK9 and blocks its interaction with LDL receptors, offering antibody-like LDL lowering without an injection.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
